Compass Therapeutics (CMPX) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Protalix BioTherapeutics (DE) (PLX) has outperformed Compass Therapeutics (CMPX) over the past year, gaining 8.4% versus a loss of 71.7%. Over five years, PLX leads with a +120.3% price change compared with -68.2% for CMPX. Protalix BioTherapeutics (DE) is the larger company by market cap ($216.7 million vs $177.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | PLX |
|---|---|---|
| Share price | $0.9872 | $2.69 |
| Market cap | $177.78M | $216.74M |
| 1-day change | -3.22% | -0.74% |
| YTD return | -81.01% | +50.56% |
| 1-year return | -71.75% | +8.40% |
| 5-year return | -68.22% | +120.33% |
| P/E ratio (TTM) | — | 11.70 |
| Forward P/E | — | 4.34 |
| EPS (TTM) | $-0.39 | $0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.88 | $3.19 |
| 52-week low | $0.829 | $1.60 |
| Distance from 52-week high | -85.65% | -15.67% |
| Analyst consensus | buy | none |
| Avg. price target upside | +452.07% | +308.92% |
| Average volume | 4.06M | 732.64K |
| Shares outstanding | 180.09M | 80.57M |
| Employees | 39 | 226 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLX has outperformed CMPX by 80.1 percentage points over the past year.
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
CMPX vs PLX FAQ
Which is bigger, Compass Therapeutics or Protalix BioTherapeutics (DE)?
Protalix BioTherapeutics (DE) (PLX) is larger, with a market capitalization of $216.74M compared with $177.78M for Compass Therapeutics (CMPX).
Which stock has performed better over the past year, CMPX or PLX?
PLX returned +8.40% over the past 12 months, compared with -71.75% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and Protalix BioTherapeutics (DE) in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.